HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.

AbstractINTRODUCTION:
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with no effective targeted therapy. Inducible nitric oxide synthase (iNOS) is associated with poor survival in patients with breast cancer by increasing tumor aggressiveness. This work aimed to investigate the potential of iNOS inhibitors as a targeted therapy for TNBC. We hypothesized that inhibition of endogenous iNOS would decrease TNBC aggressiveness by reducing tumor initiation and metastasis through modulation of epithelial-mesenchymal transition (EMT)-inducing factors.
METHODS:
iNOS protein levels were determined in 83 human TNBC tissues and correlated with clinical outcome. Proliferation, mammosphere-forming efficiency, migration, and EMT transcription factors were assessed in vitro after iNOS inhibition. Endogenous iNOS targeting was evaluated as a potential therapy in TNBC mouse models.
RESULTS:
High endogenous iNOS expression was associated with worse prognosis in patients with TNBC by gene expression as well as immunohistochemical analysis. Selective iNOS (1400 W) and pan-NOS (L-NMMA and L-NAME) inhibitors diminished cell proliferation, cancer stem cell self-renewal, and cell migration in vitro, together with inhibition of EMT transcription factors (Snail, Slug, Twist1, and Zeb1). Impairment of hypoxia-inducible factor 1α, endoplasmic reticulum stress (IRE1α/XBP1), and the crosstalk between activating transcription factor 3/activating transcription factor 4 and transforming growth factor β was observed. iNOS inhibition significantly reduced tumor growth, the number of lung metastases, tumor initiation, and self-renewal.
CONCLUSIONS:
Considering the effectiveness of L-NMMA in decreasing tumor growth and enhancing survival rate in TNBC, we propose a targeted therapeutic clinical trial by re-purposing the pan-NOS inhibitor L-NMMA, which has been extensively investigated for cardiogenic shock as an anti-cancer therapeutic.
AuthorsSergio Granados-Principal, Yi Liu, Maria L Guevara, Elvin Blanco, Dong Soon Choi, Wei Qian, Tejal Patel, Angel A Rodriguez, Joseph Cusimano, Heidi L Weiss, Hong Zhao, Melissa D Landis, Bhuvanesh Dave, Steven S Gross, Jenny C Chang
JournalBreast cancer research : BCR (Breast Cancer Res) Vol. 17 Pg. 25 (Feb 22 2015) ISSN: 1465-542X [Electronic] England
PMID25849745 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Activating Transcription Factor 3
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Transforming Growth Factor beta
  • Nitric Oxide Synthase Type II
Topics
  • Activating Transcription Factor 3 (metabolism)
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cell Line, Tumor
  • Cell Movement (drug effects, genetics)
  • Cell Proliferation (drug effects)
  • Cell Transformation, Neoplastic (drug effects, genetics)
  • Disease Models, Animal
  • Endoplasmic Reticulum Stress
  • Enzyme Inhibitors (pharmacology)
  • Epithelial-Mesenchymal Transition (genetics)
  • Female
  • Gene Expression
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit (metabolism)
  • Lung Neoplasms (secondary)
  • Mice
  • Molecular Targeted Therapy
  • Neoplasm Invasiveness
  • Nitric Oxide Synthase Type II (antagonists & inhibitors, genetics, metabolism)
  • Prognosis
  • Transforming Growth Factor beta (metabolism)
  • Triple Negative Breast Neoplasms (drug therapy, genetics, metabolism, mortality, pathology)
  • Tumor Burden (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: